Researchers have traced a potential pathway behind rare post-vaccine myocarditis to two immune signaling proteins, CXCL10 and IFN-gamma. In lab and animal models, certain immune cells, when exposed to mRNA vaccine components, released these signals, which then drove inflammation capable of affecting heart tissue. This doesn’t mean the vaccines are unsafe; it means we’re finally beginning to see, in detail, how a tiny fraction of people may react differently.

Crucially, the same study showed that blocking these inflammatory signals reduced heart-related damage without shutting down the broader immune response, hinting at future ways to refine vaccines or protect at‑risk groups. Compounds like genistein offered partial protection in experiments, but researchers insist this is not a ready-made treatment. Their message is clear: the risk remains very low, COVID-19 itself is far more dangerous, and understanding these mechanisms is about making a strong tool even safer.